MedTrace Logo

Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination: Feasibility Trial

NCT02535845 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2024-01-30

Study results available
· View outcomes & findings →

Summary

HPV vaccine coverage among adolescents in the US is suboptimal. This is particularly true among traditionally underserved adolescents. Few parent-targeted interventions have focused on the parental decision-making process. Self-persuasion, generating one's own arguments for engaging in a behavior, may be an effective means to influence parents' motivation to vaccinate their children. In a three-phase study, investigators are using quantitative and qualitative research methods to develop and refine a tablet-based self-persuasion intervention for parents who are undecided about the HPV vaccine. This clinical trial submission focuses on the third phase of the study (the second stage is also registered in clinical trials).

Conditions

  • Human Papillomavirus Vaccines

Interventions

BEHAVIORAL

Project Voice

Project Voice tablet-based intervention plus informational video

BEHAVIORAL

HPV Informational Video

Informational video only

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Southern Methodist University

    collaborator OTHER

  • Parkland Health and Hospital System

    collaborator OTHER

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Jasmin A Tiro, PhD · UT Southwestern Medical Center

  • Austin S Baldwin, PhD · Southern Methodist University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
11 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-12-21
Primary Completion
2019-01-31
Completion
2019-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02535845 on ClinicalTrials.gov